Collaborative virtual screening to elaborate an imidazo[1,2-<i>a</i>]pyridine hit series for visceral leishmaniasis.

Akao, Yuichiro; Canan, Stacie; Cao, Yafeng; Condroski, Kevin; Engkvist, Ola; Itono, Sachiko; Kaki, Rina; Kimura, Chiaki; Kogej, Thierry; Nagaoka, Kazuya; Naito, Akira; Nakai, Hiromi; Pairaudeau, Garry; Radu, Constantin; Roberts, Ieuan; Shimada, Mitsuyuki; Shum, David; Watanabe, Nao-Aki; Xie, Huanxu; Yonezawa, Shuji; Yoshida, Osamu; Yoshida, Ryu; Mowbray, Charles; Perry, Benjamin

Collaborative virtual screening to elaborate an imidazo[1,2-a]pyridine hit series for visceral leishmaniasis.

Akao, Yuichiro; Canan, Stacie; Cao, Yafeng; Condroski, Kevin; Engkvist, Ola; Itono, Sachiko; Kaki, Rina; Kimura, Chiaki; Kogej, Thierry; Nagaoka, Kazuya; Naito, Akira; Nakai, Hiromi; Pairaudeau, Garry; Radu, Constantin; Roberts, Ieuan; Shimada, Mitsuyuki; Shum, David; Watanabe, Nao-Aki; Xie, Huanxu; Yonezawa, Shuji; Yoshida, Osamu; Yoshida, Ryu; Mowbray, Charles; Perry, Benjamin.

Afiliação

Akao Y; Takeda Pharmaceutical Company Limited 26-1 Muraoka-Higashi 2-chrome Fujisawa Kanagawa 251-8555 Japan.
Canan S; Celgene Corporation, Celgene Global Health 10300 Campus Point Drive San Diego California 92121 USA.
Cao Y; WuXi AppTec Company Ltd. 666 Gaoxin Road, East Lake High-Tech Development Zone Wuhan 430075 People's Republic of China.
Condroski K; Celgene Corporation, Celgene Global Health 10300 Campus Point Drive San Diego California 92121 USA.
Engkvist O; AstraZeneca Discovery Sciences, R&D AstraZeneca Gothenburg Sweden.
Itono S; Takeda Pharmaceutical Company Limited 26-1 Muraoka-Higashi 2-chrome Fujisawa Kanagawa 251-8555 Japan.
Kaki R; Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan.
Kimura C; Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan.
Kogej T; AstraZeneca Discovery Sciences, R&D AstraZeneca Gothenburg Sweden.
Nagaoka K; Eisai Co., Ltd 1-3,Tokodai 5-chome Tsukuba Ibaraki 300-2635 Japan.
Naito A; Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan.
Nakai H; Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan.
Pairaudeau G; AstraZeneca, Discovery Sciences, R&D AstraZeneca Cambridge UK.
Radu C; Institut Pasteur Korea 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu Seongnam-si Gyeonggi-do 13488 Republic of Korea.
Roberts I; AstraZeneca, Discovery Sciences, R&D AstraZeneca Cambridge UK.
Shimada M; Takeda Pharmaceutical Company Limited 26-1 Muraoka-Higashi 2-chrome Fujisawa Kanagawa 251-8555 Japan.
Shum D; Institut Pasteur Korea 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu Seongnam-si Gyeonggi-do 13488 Republic of Korea.
Watanabe NA; Eisai Co., Ltd 1-3,Tokodai 5-chome Tsukuba Ibaraki 300-2635 Japan.
Xie H; WuXi AppTec Company Ltd. 666 Gaoxin Road, East Lake High-Tech Development Zone Wuhan 430075 People's Republic of China.
Yonezawa S; Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan.
Yoshida O; Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan.
Yoshida R; Shionogi & Co., Ltd 3-1-1, Futaba-cho Toyonaka-shi Osaka Japan.
Mowbray C; Drugs for Neglected Diseases initiative 15 Chemin Louis Dunant Geneva 1202 Switzerland bperry@dndi.org.
Perry B; Drugs for Neglected Diseases initiative 15 Chemin Louis Dunant Geneva 1202 Switzerland bperry@dndi.org.

RSC Med Chem ; 12(3): 384-393, 2021 Jan 21.

Article em En | MEDLINE | ID: mdl-34041487

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Screening_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article